- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06452147
Anestesia y trastornos neurocognitivos perioperatorios en pacientes ancianos sometidos a prueba de plataforma de cirugía de fractura de cadera (ensayo de plataforma ANDES) (ANDES platform)
Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial): A Pragmatic Multi-arm, Adaptive, Open Label, Multicenter Randomized Controlled Platform Trial to Assess the Effect of Different Enhanced Anesthesia Technique in Perioperative Neurocognitive Function, as Compared to Standard Anesthesia Care in the Elderly Patients Undergoing Hip Fracture
The ANDES Platform Trial is a pragmatic, multicenter, adaptive randomized controlled platform trial in patients aged 65 years or older undergoing surgery for hip fracture. The trial evaluates whether enhanced anesthesia techniques reduce perioperative neurocognitive disorders compared with standard anesthesia care.
The platform includes two randomization processes. In the first randomization, eligible participants are assigned to an active platform intervention-currently a preoperative regional nerve block or perioperative intravenous lidocaine infusion-or to a shared standard-anesthesia control. Participants for whom general anesthesia is planned may also enter a second, nested randomization and are assigned in a fixed 1:1 ratio to total intravenous anesthesia or volatile inhalational anesthesia, regardless of whether they participate in the first randomization.
A non-surgical cognitive control cohort is included to characterize changes in cognitive test performance over time without exposure to surgery or study interventions. The Data Monitoring Committee reviews accumulating trial data and makes recommendations to the Trial Steering Committee, which determines whether platform interventions should continue, be modified, advance, or stop.
Descripción general del estudio
Estado
Descripción detallada
The ANDES Platform Trial is a pragmatic, multicenter, adaptive platform trial designed to evaluate anesthesia strategies for reducing perioperative neurocognitive disorders in older patients undergoing hip fracture surgery.
The trial includes two related randomization processes.
In the first randomization, participants who meet the eligibility criteria for a specific platform intervention are randomly assigned to that intervention or to shared standard anesthesia care. The current platform interventions include preoperative regional nerve block and perioperative intravenous lidocaine infusion. Each intervention is compared with control participants who were eligible for randomization to that intervention.
Participants for whom the responsible anesthesiologist plans to use general anesthesia may enter a second, nested randomization, irrespective of their participation in the first randomization. These participants are assigned in a fixed 1:1 ratio to one of two anesthetic-maintenance strategies: total intravenous anesthesia, for which propofol-based maintenance is recommended, or volatile anesthesia, for which maintenance mainly with sevoflurane or isoflurane is recommended following intravenous induction.
Patients and treating clinicians are not blinded because of the nature of the interventions. Where implemented as specified in the protocol, outcome assessors remain unaware of treatment allocation, and statistical analyses are conducted using blinded treatment codes.
The study also includes a non-surgical cognitive control cohort. Members of this cohort do not undergo study randomization and do not receive any trial intervention. The cohort is used to help characterize changes associated with repeated cognitive testing and changes in cognition over time in the absence of surgery.
The platform allows interventions to be introduced, modified, advanced, or discontinued in accordance with the master protocol and applicable intervention-specific subprotocols. Accumulating safety and effectiveness data are reviewed by the independent Data Monitoring Committee. The committee makes recommendations to the Trial Steering Committee, which is responsible for platform decisions in accordance with the prespecified adaptive decision framework.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ting Li, MD, PhD
- Número de teléfono: 13587876896
- Correo electrónico: liting1021@aliyun.com
Ubicaciones de estudio
-
-
Zhejiang
-
Dongyang, Zhejiang, Porcelana
- Inscripción por invitación
- Dongyang People's Hospital
-
Hangzhou, Zhejiang, Porcelana
- Inscripción por invitación
- Zhejiang Provincial People's Hospital
-
Jinhua, Zhejiang, Porcelana
- Reclutamiento
- Jinhua Municipal Central Hospital
-
Contacto:
- Yuanliang Chen, MD
- Correo electrónico: chenyl1186@163.com
-
Lishui, Zhejiang, Porcelana
- Reclutamiento
- Lishui People's Hospital
-
Contacto:
- Jimin Wu, MD
- Correo electrónico: wujimin2022@163.com
-
Lishui, Zhejiang, Porcelana
- Reclutamiento
- Lishui Central Hospital, the Fifth Hospital Affiliated to Wenzhou Medical University
-
Contacto:
- Chuanguang Wang, MD
- Correo electrónico: wcg0033@wmu.edu.cn
-
Ningbo, Zhejiang, Porcelana
- Reclutamiento
- Ningbo No.2 Hospital
-
Contacto:
- Junping Chen, MD
- Correo electrónico: 13858222873@163.com
-
Ningbo, Zhejiang, Porcelana
- Reclutamiento
- Ningbo No.6 Hospital
-
Contacto:
- Liyong Yuan, MD
- Correo electrónico: ylysgl@hotmail.com
-
Quzhou, Zhejiang, Porcelana
- Reclutamiento
- Quzhou People's Hospital
-
Contacto:
- Xiangyu Fang, MD
- Correo electrónico: 15811076@qq.com
-
Taizhou, Zhejiang, Porcelana
- Inscripción por invitación
- Taizhou Central Hospital
-
Taizhou, Zhejiang, Porcelana
- Inscripción por invitación
- Zhejiang Taizhou Hospital
-
Wenling, Zhejiang, Porcelana
- Reclutamiento
- The First People's Hospital of Wenling
-
Contacto:
- Yanguo Zheng, MD
- Correo electrónico: zygm15@126.com
-
Wenzhou, Zhejiang, Porcelana, 325000
- Reclutamiento
- The Second Affilliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
-
Contacto:
- Ting Li, PhD
- Número de teléfono: 13587876896
- Correo electrónico: liting1021@aliyun.com
-
Investigador principal:
- Ting Li, PhD
-
Sub-Investigador:
- Bingwu Huang, PhD
-
Wenzhou, Zhejiang, Porcelana, 325000
- Inscripción por invitación
- The First Affiliated Hospital of Wenzhou Medical University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Aged 65 years and older.
- Patients with unilateral hip fracture (including femoral neck, femoral head, intertrochanteric and subtrochanteric fractures) are scheduled for surgical treatment.
- American Society of Anesthesiologists (ASA) physical status IV or below.
- The patients or family members provide written informed consent.
- Additional inclusion criteria may pertain to specific interventions and will be described in relevant sub-protocols.
Exclusion Criteria:
- Patients with multiple trauma or fractures (excluding trauma that the researcher judges will not affect the patient's overall recovery, such as simple spinal compression fractures, mild soft tissue contusions, fractures of hands and feet, etc.);
- Two or more anesthetic surgeries are required.
- Patients with an obvious history of head trauma (such as loss of consciousness for more than 5 minutes, post-traumatic amnesia, etc.);
- Patients who the researcher believes are unable to complete the assessment of primary outcome;
- Additional exclusion criteria may pertain to specific interventions and will be described in relevant sub-protocols.
Additional exclusion criteria for the nerve block randomization:
- Contraindications to nerve block, including allergy to local anesthetics, other contraindications specified in the applicable prescribing information, infection at the puncture site, or refusal to receive nerve block;
- The investigator considers the participant unsuitable for nerve block because of conditions such as a history of severe peripheral neuropathy or severe coagulation dysfunction;
- Receipt of nerve block before randomization during the current hospitalization.
Additional exclusion criteria for the intravenous lidocaine randomization:
- Allergy to lidocaine;
- Severe hepatic impairment or renal insufficiency for which the investigator considers the participant unsuitable for enrollment.
Eligibility Criteria for nonsurgical cognitive control participants:
A nonsurgical cognitive control cohort may be recruited from emergency departments, outpatient clinics, inpatient wards, or the community for standardization of neurocognitive assessments. These participants will be matched as far as possible to surgical participants by age and education level. Except for criteria related to hip fracture surgery and trial interventions, the same general inclusion and exclusion criteria will apply. Nonsurgical cognitive control participants must not undergo surgery or anesthesia during the observation period; participants who undergo surgery during follow-up will be excluded from the nonsurgical cognitive control cohort.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Nerve block
Participants receive standard anesthesia care plus preoperative regional nerve block, as described in sub-trial protocol 1. Participants in this arm who are planned to undergo general anesthesia may also enter the second nested randomization and be assigned in a 1:1 ratio to total intravenous anesthesia or volatile anesthesia maintenance. |
Participants receive a preoperative regional nerve block as soon as possible after randomization. Ultrasound guidance is recommended, and fascia iliaca block is the recommended block technique. Standard anesthesia care consists of routine general or regional anesthesia according to usual practice at each study center. Participants randomized to the shared control group do not receive protocol-specified trial interventions unless otherwise required by the Trial Steering Committee. Changes to standard anesthesia care are made in accordance with the prespecified adaptive decision framework. The independent Data Monitoring Committee reviews accumulating data and makes recommendations to the Trial Steering Committee, which makes the final platform decisions. For participants randomized to the nerve block group, 1.33% bupivacaine liposome is recommended as a long-acting local anesthetic, with a maximum dose not exceeding 133 mg, to maintain the continuity of the nerve block effect. For participants randomized to the nerve block group, regular local anesthetic, such as bupivacaine or ropivacaine, may be used with continuous electronic analgesic pump infusion or multiple single injections to maintain the continuity of the nerve block effect. Among participants who are eligible under the master protocol and for whom general anesthesia is planned, anesthetic maintenance may be assigned by the second nested randomization to total intravenous anesthesia maintenance in a 1:1 ratio. Total intravenous anesthesia maintenance is recommended to be mainly propofol-based, and analgesics such as remifentanil or fentanyl are recommended. Among participants who are eligible under the master protocol and for whom general anesthesia is planned, anesthetic maintenance may be assigned by the second nested randomization to volatile anesthesia maintenance in a 1:1 ratio. Following intravenous induction, anesthesia maintenance mainly with sevoflurane or isoflurane is recommended. |
|
Experimental: Intravenous infusion of lidocaine
Participants receive standard anesthesia care plus perioperative intravenous lidocaine infusion, as described in sub-trial protocol 2. Participants in this arm who are planned to undergo general anesthesia may also enter the second nested randomization and be assigned in a 1:1 ratio to total intravenous anesthesia or volatile anesthesia maintenance. |
Standard anesthesia care consists of routine general or regional anesthesia according to usual practice at each study center. Participants randomized to the shared control group do not receive protocol-specified trial interventions unless otherwise required by the Trial Steering Committee. Changes to standard anesthesia care are made in accordance with the prespecified adaptive decision framework. The independent Data Monitoring Committee reviews accumulating data and makes recommendations to the Trial Steering Committee, which makes the final platform decisions. Among participants who are eligible under the master protocol and for whom general anesthesia is planned, anesthetic maintenance may be assigned by the second nested randomization to total intravenous anesthesia maintenance in a 1:1 ratio. Total intravenous anesthesia maintenance is recommended to be mainly propofol-based, and analgesics such as remifentanil or fentanyl are recommended. Among participants who are eligible under the master protocol and for whom general anesthesia is planned, anesthetic maintenance may be assigned by the second nested randomization to volatile anesthesia maintenance in a 1:1 ratio. Following intravenous induction, anesthesia maintenance mainly with sevoflurane or isoflurane is recommended. Participants randomized to the lidocaine group receive ECG monitoring, oxygen saturation monitoring, blood pressure monitoring, and an open intravenous route on the morning of surgery. It is recommended to start the infusion of lidocaine as soon as possible in the ward. A portable electronic infusion pump is recommended for drug delivery. The loading dose is 1 mg/kg, and the maintenance dose range is 1 to 2 mg/kg/h. The specific dose is determined by the anesthesiologist according to the patient's condition. The infusion ends when the patient leaves the post-anesthesia care unit after surgery, and the infusion time and total amount are recorded. Intravenous infusion of lidocaine should be administered under ECG monitoring. |
|
Comparador activo: Shared standard anesthesia care
Participants receive standard anesthesia care. Participants for whom general anesthesia is planned may also enter the second nested randomization and be assigned in a fixed 1:1 ratio to total intravenous anesthesia maintenance or volatile anesthesia maintenance. |
Standard anesthesia care consists of routine general or regional anesthesia according to usual practice at each study center. Participants randomized to the shared control group do not receive protocol-specified trial interventions unless otherwise required by the Trial Steering Committee. Changes to standard anesthesia care are made in accordance with the prespecified adaptive decision framework. The independent Data Monitoring Committee reviews accumulating data and makes recommendations to the Trial Steering Committee, which makes the final platform decisions. Among participants who are eligible under the master protocol and for whom general anesthesia is planned, anesthetic maintenance may be assigned by the second nested randomization to total intravenous anesthesia maintenance in a 1:1 ratio. Total intravenous anesthesia maintenance is recommended to be mainly propofol-based, and analgesics such as remifentanil or fentanyl are recommended. Among participants who are eligible under the master protocol and for whom general anesthesia is planned, anesthetic maintenance may be assigned by the second nested randomization to volatile anesthesia maintenance in a 1:1 ratio. Following intravenous induction, anesthesia maintenance mainly with sevoflurane or isoflurane is recommended. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of Neurocognitive Disorders (NCD) events rate during the first 7 postoperative days
Periodo de tiempo: during the first 7 postoperative days
|
Neurocognitive Disorders includes:
Neurocognitive function is assessed at screening, postoperative day 3, and postoperative day 7. If discharge occurs on postoperative day 5 or 6, the final assessment is performed on the day of discharge; if discharge occurs on postoperative day 4, no repeat cognitive assessment is performed. A participant with postoperative delirium and/or postoperative neurocognitive decline is classified as positive for the primary outcome. |
during the first 7 postoperative days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Duración de la hospitalización
Periodo de tiempo: días desde el ingreso hasta el alta, una media de 7 días
|
días desde el ingreso hasta el alta, una media de 7 días
|
|
|
Días en casa hasta 30 días después de la cirugía (DAH30)
Periodo de tiempo: hasta 30 días después de la cirugía
|
hasta 30 días después de la cirugía
|
|
|
Mortalidad por todas las causas a 1 año
Periodo de tiempo: 1 año después de la cirugía
|
1 año después de la cirugía
|
|
|
Subtypes, severity, and duration of delirium
Periodo de tiempo: during the first 7 postoperative days
|
Using CAM-S, and in units of days from the onset of delirium symptoms to the disappearance of symptoms or when the patient is discharged. |
during the first 7 postoperative days
|
|
Neurocognitive decline in postoperative 7 days
Periodo de tiempo: during the first 7 postoperative days
|
Neurocognitive decline was mesaured by: Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA), or neuropsychological tests containing 5 cognitive domains (1. digit span test (DST); 2. trail making test (TMT); 3. Boston naming test (BNT); 4. auditory verbal learning test-Huashan version (AVLT-H);5. clock drawing test (CDT).), or active report of patients or family members. |
during the first 7 postoperative days
|
|
Delayed neurocognitive recovery during 30 postoperative days
Periodo de tiempo: Postoperative day 11 ± 3 days if the hospital stay exceeds 7 days, and postoperative day 30 ± 7 days.
|
This was mesaured by: Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA), or neuropsychological tests containing 5 cognitive domains(1. digit span test (DST); 2. trail making test (TMT); 3. Boston naming test (BNT); 4. auditory verbal learning test-Huashan version (AVLT-H);5. clock drawing test (CDT).), or active report of patients or family members. |
Postoperative day 11 ± 3 days if the hospital stay exceeds 7 days, and postoperative day 30 ± 7 days.
|
|
Hospital Anxiety and Depression Scale (HADs)
Periodo de tiempo: At screening, postoperative day 5 ± 2 days, postoperative day 11 ± 3 days if the hospital stay exceeds 7 days, postoperative day 30 ± 7 days, and postoperative month 12 ± 1 month.
|
At screening, postoperative day 5 ± 2 days, postoperative day 11 ± 3 days if the hospital stay exceeds 7 days, postoperative day 30 ± 7 days, and postoperative month 12 ± 1 month.
|
|
|
Acute pain before and after surgery
Periodo de tiempo: Before surgery and on postoperative days 1, 2, and 3.
|
Using Visual Analogue Scale (VAS) |
Before surgery and on postoperative days 1, 2, and 3.
|
|
Incidence of important intraoperative adverse events requiring treatment
Periodo de tiempo: During anesthesia on the day of surgery.
|
Important intraoperative adverse events are defined as adverse events requiring treatment. |
During anesthesia on the day of surgery.
|
|
Complications (except cognitive impairment)
Periodo de tiempo: during postoperation 30 days
|
including pulmonary infection, myocardial infarction, renal failure, gastrointestinal obstruction, etc. |
during postoperation 30 days
|
|
In-hospital and 30-day mortality
Periodo de tiempo: During hospitalization and within 30 days after surgery.
|
During hospitalization and within 30 days after surgery.
|
|
|
Score of EuroQol Five Dimensions Questionnaire (EQ-5D)
Periodo de tiempo: 1 week before fracture (retrospective assessment), and 1, 3, 6, 9, and 12 months after surgery.
|
Quality of life will be assessed using the EuroQol Five Dimensions Questionnaire (EQ-5D). Prefracture quality of life will be assessed retrospectively for the week before fracture. |
1 week before fracture (retrospective assessment), and 1, 3, 6, 9, and 12 months after surgery.
|
|
Incidence of postoperative Neurocognitive Disorders (NCD)
Periodo de tiempo: Up to 12 months after surgery.
|
Postoperative neurocognitive disorder will be determined as a binary outcome according to the prespecified neurocognitive assessment framework. Cognitive assessments, including the Mini-Mental State Examination, Montreal Cognitive Assessment, multidomain neuropsychological tests, and patient- or caregiver-reported cognitive change, will be integrated according to the prespecified criteria to determine whether postoperative neurocognitive disorder is present. The reported outcome is the proportion of participants with postoperative neurocognitive disorder. |
Up to 12 months after surgery.
|
|
Severity of postoperative Neurocognitive Disorders (NCD)
Periodo de tiempo: At 12 months after surgery
|
At 12 months after surgery
|
|
|
Type of postoperative Neurocognitive Disorders (NCD)
Periodo de tiempo: within 1 year after surgery (long-term)
|
Using Hachinski Ischemic Scale (HIS) combined with clinical symptoms and auxiliary examination to mesaure the type of postoperative NCD. HIS ≥7 was considered as vascular cognitive impairment. |
within 1 year after surgery (long-term)
|
|
Instrumental Activities of Daily Living (IADL)
Periodo de tiempo: At screening for the week before fracture, postoperative day 5 ± 2 days, postoperative day 11 ± 3 days if the hospital stay exceeds 7 days, postoperative day 30 ± 7 days, and postoperative months 3, 6, 9, and 12.
|
At screening for the week before fracture, postoperative day 5 ± 2 days, postoperative day 11 ± 3 days if the hospital stay exceeds 7 days, postoperative day 30 ± 7 days, and postoperative months 3, 6, 9, and 12.
|
|
|
Health economic outcomes
Periodo de tiempo: During hospitalization; from hospital discharge to the 1-month follow-up; and for each interval from the previous follow-up visit to the 3-, 6-, 9-, and 12-month follow-up visits.
|
Health economic outcomes include direct medical costs, direct nonmedical costs, and indirect costs. Direct medical costs include anesthesia and related costs, surgical treatment costs, medication and biological product costs, diagnosis-related costs, supportive treatment costs, rehabilitation costs, blood and blood product costs, and consumable material costs. Direct nonmedical costs include paid caregiver costs, transportation costs, and accommodation costs related to medical care. Indirect costs mainly include productivity losses of family members or unpaid caregivers due to accompanying or caring for the participant. |
During hospitalization; from hospital discharge to the 1-month follow-up; and for each interval from the previous follow-up visit to the 3-, 6-, 9-, and 12-month follow-up visits.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of adverse events
Periodo de tiempo: From enrollment to hospital discharge, an average of 7 days.
|
We will collect the following known potential risks of general and local anesthesia from the start of the intervention to the subject's discharge and assess the overall incidence:
|
From enrollment to hospital discharge, an average of 7 days.
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Ting Li, MD, PhD, Second Affiliated Hospital of Wenzhou Medical University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Heridas y Lesiones
- Lesiones en las piernas
- Trastornos neurocognitivos
- Trastornos cognitivos
- Fracturas, Hueso
- Fracturas Femorales
- Lesiones de cadera
- Disfunción congnitiva
- Fracturas de cadera
- Demencia
- Procedimientos quirúrgicos, operativo
- Anestesia y analgesia
- Procedimientos neurociruúrgicos
- Anestesia, conducción
- Anestesia
- Denervación
- Bloqueo nervioso
Otros números de identificación del estudio
- SAHoWMU-CR2024-03-112
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Within 1 year after study completion, study data and related documentation will be made available upon request to the principal investigator or data coordinating center. The documentation will include annotated case report forms, descriptions of the structure, variables, and content of each dataset, the final protocol, study procedures, data collection forms, descriptions of variable recoding, and lists and links to major publications. Key datasets will be archived as appropriate.
Marco de tiempo para compartir IPD
Available within 1 year after study completion.
Criterios de acceso compartido de IPD
Requests should be submitted to the principal investigator or data coordinating center.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .